Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
544 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01062425 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 261 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03397953 | Vinorelbine for Recurrent ACLC | completed | Phase 2 | 20 | Children's Cancer Group, ChinaNETWORK | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01609790 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors |
| completed |
| Phase 2 |
| 137 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Jul 21, 2022 |
| clinicaltrials |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT01808820 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | completed | Phase 1 | 20 | Macarena De La Fuente, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05447195 | Phase 2 Study of CAN008 in Subjects With GBM | unknown | Phase 2 | 117 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05099068 | Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)(PLANET) | unknown | N/A | 500 | Centre Leon BerardOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | completed | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02968940 | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | completed | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT04599647 | EAP for the Treatment of Glioblastoma With PVSRIPO | no longer available | — | — | Istari Oncology, Inc.INDUSTRY | 1 | Jun 29, 2022 | clinicaltrials |
| NCT02644291 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | completed | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02663271 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | terminated | Phase 2 | 10 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT02330562 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | completed | Phase 1 / Phase 2 | 121 | CelgeneINDUSTRY | 2 | Jun 8, 2022 | clinicaltrials |
| NCT01664182 | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05399524 | Functional and Ultrasound Guided Resection of Glioblastoma(FUTURE-GB) | unknown | N/A | 357 | University of OxfordOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02709616 | Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)(PERCELLVAC) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT02808364 | Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)(PerCellVac2) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02871843 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas(G-FORCE-1) | completed | Phase 1 | 19 | EpicentRx, Inc.INDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT03216499 | HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma(PT2385) | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04219475 | Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients(PROPHETIC) | suspended | — | 1,000 | OncoHost Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02794883 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | completed | Phase 2 | 36 | Northwestern UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT02973256 | Oncological Care for Patients With Meningioma(ATYPICMENING) | unknown | — | 1,204 | University Hospital, MontpellierOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03390569 | Exercise in Patients With Glioblastoma | completed | N/A | 54 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | completed | Phase 2 | 80 | Duke UniversityOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02843230 | Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI | completed | — | 30 | Massachusetts General HospitalOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT00303849 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | completed | Phase 1 / Phase 2 | 33 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02359097 | Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma | completed | N/A | 29 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04516733 | Precoce Medical Care by the Mobil Support for Patients With Glioblastoma(GLIOSUPPORT) | completed | N/A | 35 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT02270034 | Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05265793 | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN) | unknown | Phase 2 | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT01925573 | Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | terminated | N/A | 7 | University of Maryland, BaltimoreOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03341806 | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | completed | Phase 1 | 13 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 4, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jul 26, 2022source: clinicaltrials